[ Price : $8.95]
FDA accepts for review Revolution Medicines' NDA for daraxonrasib, an investigational oral RAS-targeted therapy for patients with ...[ Price : $8.95]
Attorney Megan Robertsons analysis of 2026 FDA Warning Letters shows that CDER has been the most active Center, going after telehe...[ Price : $8.95]
FDA releases the form FDA-483 issued following a 2026 inspection at the CSL Behring biological drug manufacturing facility in Marb...[ Price : $8.95]
FDA investigators cite contract research organization Cliantha Research over data integrity, documentation and clinical research d...[ Price : $8.95]
A citizen petition urges FDA to establish a regulatory framework for implantable brain-computer interfaces designed to expand huma...[ Price : $8.95]
An analysis by PharmaVoice says FDA could remain without a Senate-confirmed commissioner for months as political and procedural hu...[ Price : $8.95]
FDA acting commissioner Kyle Diamantas uses a Fox News editorial to tout agency steps he says are providing new jobs for American ...[ Price : $8.95]
FDA names Dexcom as the first participant in its new Technology-Enabled Meaningful Patient Outcomes for Digital Health Devices Pil...